NICE recommends all-oral treatment for multiple myeloma19 January 2023 | By Catherine Eckford (European Pharmaceutical Review)Ninlaro® (ixazomib) plus lenalidomide and dexamethasone has been recommended by NICE for relapsed/refractory multiple myeloma patients who have had two or three lines of therapy.
Pfizer offers 1.2 billion in poorer countries access to full medicine portfolio18 January 2023 | By Catherine Eckford (European Pharmaceutical Review)Pfizer has expanded its not-for-profit initiative ‘An Accord for a Healthier World’ to enable 45 lower-income countries access to its full product portfolio.
mRNA vaccine trial shows efficiency in older adults with RSV18 January 2023 | By Catherine Eckford (European Pharmaceutical Review)Moderna's mRNA vaccine targeting respiratory syncytial virus (RSV) in older adults demonstrated promising efficacy in a Phase III trial.
UK medical cannabis manufacturer granted GMP registration18 January 2023 | By Catherine Eckford (European Pharmaceutical Review)The UK Medicines and Healthcare products Regulatory Agency (MHRA) has granted a UK manufacturing facility good manufacturing practice (GMP) registration for its cannabis API.
UK ATMP clinical trials report 2022 published17 January 2023 | By Catherine Eckford (European Pharmaceutical Review)T cells were revealed as the most commonly investigated cell type continuing to increase, found CGT Catapult's 2022 UK ATMP clinical trials report.
MHRA approves biosimilar for vision disorders in Great Britain17 January 2023 | By Catherine Eckford (European Pharmaceutical Review)A marketing authorization for Ximluci® biosimilar referencing Lucentis® (ranibizumab) in Great Britain has been issued by the Medicines and Healthcare products Regulatory Agency (MHRA).
Potential treatment identified for septic patients17 January 2023 | By Catherine Eckford (European Pharmaceutical Review)CER-001 is a potentially game-changing treatment for septic patients at high risk of acute kidney injury, suggested a ABIONYX Pharma VP.
FDA approves long-acting injectable for schizophrenia and bipolar disorder16 January 2023 | By Catherine Eckford (European Pharmaceutical Review)Schizophrenia and bipolar I disorder patients can be offered Rykindo® as a bi-weekly long-acting risperidone injection, as a result of the FDA's approval.
Switzerland and US sign drug inspection agreement16 January 2023 | By Catherine Eckford (European Pharmaceutical Review)To promote Good Manufacturing Practice, Switzerland and the US have signed a Mutual Recognition Agreement to improve pharmaceutical drug inspection.
Moderna joins the Association of the British Pharmaceutical Industry16 January 2023 | By Catherine Eckford (European Pharmaceutical Review)To support the UK’s investments in manufacturing and R&D, Moderna has joined the Association of the British Pharmaceutical Industry (ABPI).
T-cell therapy helps overcome stem cell transplant viral infections13 January 2023 | By Catherine Eckford (European Pharmaceutical Review)A T-cell therapy that targets six viruses commonly contracted by haematology patients after allogeneic stem cell transplantation, offered 95 percent response in a study.
Pre-filled asthma pen approved for self-administration in EU13 January 2023 | By Catherine Eckford (European Pharmaceutical Review)Tezspire is the first biologic approved in Europe for severe asthma with no phenotype or biomarker limitation, says AstraZeneca EVP.
Ph. Eur. adopts revised general monographs after adding paragraph on N-nitrosamines13 January 2023 | By Catherine Eckford (European Pharmaceutical Review)Adoption of revised general monographs 2034 and 2619 comes after inclusion of a new paragraph approaching N-nitrosamine impurities.
2022 Terra Carta Seal: three pharma companies awarded12 January 2023 | By Catherine Eckford (European Pharmaceutical Review)Two Big Pharma companies and one CDMO have been awarded the Terra Carta Seal, which recognises the efforts of global companies in their commitment to sustainability.
EC approves influenza antiviral for children over one years old12 January 2023 | By Catherine Eckford (European Pharmaceutical Review)Xofluza® offers the first novel mechanism of action for an influenza antiviral to be approved by the European Commission in almost 20 years.
